alexa Diarrhoea in a Melanoma Patient | Open Access Journals
ISSN: 2161-069X
Journal of Gastrointestinal & Digestive System
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Diarrhoea in a Melanoma Patient

Katherine Gordon1*, Keith Roberts2, Peter Coburm3 and Andy Chung Li1

1Department of Gastroenterology, Worthing Hospital Worthing, UK

2Department of Histopathology, Worthing Hospital Worthing, UK

3Department of Dermatology, Worthing Hospital Worthing, UK

Corresponding Author:
Gordon K
Department of Gastroenterology
Washington Suite, Worthing Hospital
United Kingdom
Tel: 07834523697
E-mail: [email protected]

Received Date: August 08, 2017; Accepted Date: August 30, 2017; Published Date: August 31, 2017

Citation: Gordon K, Roberts K, Coburm P, Chung Li A. (2017) Diarrhoea in a Melanoma Patient. J Gastrointest Dig Syst 7:525. doi:10.4172/2161-069X.1000525

Copyright: © 2017 Gordon K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Gastrointestinal & Digestive System

Abstract

Case report of a female with malignant melanoma, developing diarrhoea following administration of Pembrolizumab. Macroscopic investigation was normal, but histology was in keeping with lymphocytic colitis secondary to drug related injury, which is the first to be described with this immunotherapy.

Keywords

Lymphocytic colitis; Diarrhoea; Immunotherapy; Melanoma

Clinical Presentation

A 53 year old female presented to gastroenterology with a history of diarrhoea, with loose stools and frequency of up to six times a day. This was associated with nausea, vomiting and weight loss. Her past medical history included malignant melanoma, which had been excised in 2013. Recurrence was found in the previous wound site in 2015.

She had been commenced on Pembrolizumab in October 2015 following staging CT showed multiple lung metastases. She was not on any other regular medications. She had not previously suffered from diarrhoea or gastrointestinal upset. Past medical history was otherwise unremarkable. Flexible sigmoidoscopy and colonoscopy were macroscopically normal. Histology from biopsies taken is shown in Figure 1.

gastrointestinal-digestive-system-colonic-biopsies

Figure 1: Histology slides from colonic biopsies.

Question: What is the diagnosis?

The diagnosis is lymphocytic colitis secondary to Pembrolizumab. The biopsies show diffuse increase in lamina propria chronic inflammatory cells, raised numbers of intraepithelial lymphocytes and no increased thickness proof the subepithelial collagen plate. Additionally, there are acute inflammatory cells and cryptitis which is not typical of lymphocytic colitis, but indicative of injury secondary to monoclonal antibody damage. She was commenced on prednisolone and improved.

Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1), used to treat metastatic melanoma. It is an example of a checkpoint inhibitor immunotherapy, which, though effective, is associated with a variety of side effects including diarrhoea. Diarrhoea is less common with PD-1 blockade than with other immunotherapies. Management involves excluding an infective cause. Proven colitis is treated with cessation of the drug, anti-motility agents and steroids. Infliximab is recommended in severe cases.

Conclusion

There are very few reported cases of colitis secondary to pembrolizumab. The KEYNOTE-001 trial, assessing the efficacy and safety of pembrolizumab, reported an incidence of 20% of diarrhoea, however only 4 cases of proven colitis out of 411 patients on pembrolizumab in the trial [1]. To date, there is one other published case of colitis with pembrolizumab, however they describe a collagenous colitis, in contrast to this example of lymphocytic colitis [2].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 65
  • [From(publication date):
    August-2017 - Sep 23, 2017]
  • Breakdown by view type
  • HTML page views : 48
  • PDF downloads :17
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords